Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

作者：Elisabetta Sauta, M. Robin, M. Bersanelli, E. Travaglino, M. Meggendorfer, Lin-Pierre Zhao, J. C. Caballero Berrocal, C. Sala, G. Maggioni, M. Bernardi, C. di Grazia, L. Vago, G. Rivoli, L. Borin, S. D'Amico, C. Tentori, M. Ubezio, A. Campagna, Antonio Russo, D. Mannina, L. Lanino, P. Chiusolo, L. Giaccone, M. Voso, M. Riva, E. Oliva, M. Zampini, E. Riva, O. Nibourel, Marilena Bicchieri, N. Bolli, A. Rambaldi, F. Passamonti, V. Savevski, A. Santoro, U. Germing, S. Kordasti, V. Santini, M. Díez-Campelo, G. Sanz, F. Solé, W. Kern, U. Platzbecker, L. Adès, P. Fenaux, T. Haferlach, G. Castellani, M. D. della Porta · 发表于：Journal of Clinical Oncology · 年份：2023 · DOI：10.1200/jco.22.01784 · 被引用次数：186 · 研究领域：Medicine

PURPOSE Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). We aimed to provide an extensive validation of IPSS-M. METHODS A total of 2,876 patients with primary MDS from the GenoMed4All consortium were retrospectively analyzed. RESULTS IPSS-M improved prognostic discrimination across all clinical end points with respect to IPSS-R (concordance was 0.81 v 0.74 for overall survival and 0.89 v 0.76 for leukemia-free survival, respectively). This was true even in those patients without detectable gene mutations. Compared with the IPSS-R based stratification, the IPSS-M risk group changed in 46% of patients (23.6% and 22.4% of subjects were upstaged and downstaged, respectively). In patients treated with hematopoietic stem cell transplantation (HSCT), IPSS-M significantly improved the prediction of the risk of disease relapse and the probability of post-transplantation survival versus IPSS-R (concordance was 0.76 v 0.60 for overall survival and 0.89 v 0.70 for probability of relapse, respectively). In high-risk patients treated with hypomethylating agents (HMA), IPSS-M failed to stratify individual probability of response; response duration and proba...